Cavalier Investments’s Idexx Laboratories IDXX Stock Holding History

Cavalier Investments’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-3,000	Closed	-$469K	–	181
2017 Q4	$469K	Hold	3,000	–	–	0.19%	91
2017 Q3	$466K	Sell	3,000 -1,300	-30%	-$206K	0.22%	82
2017 Q2	$665K	Hold	4,300	–	–	0.37%	63
2017 Q1	$665K	Hold	4,300	–	–	0.37%	63
2016 Q4	$504K	Buy	+4,300	New	+$491K	0.32%	58

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $13.6B AUM 7.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Cavalier Investments's IDXX Position: Q1 2018 in Review

Cavalier Investments sold out of Idexx Laboratories (IDXX) in Q1 2018, closing a stake of 3,000 shares — an estimated $469K sold.

Cavalier Investments first reported a position in IDXX in Q4 2016 and held it in 5 quarters. The position peaked at $665K in Q2 2017. 646 funds tracked by Wall St. Rank hold IDXX as of Q1 2018.

Cavalier Investments reported no remaining Idexx Laboratories position as of Q1 2018 after selling out during the quarter.
Cavalier Investments sold 3,000 Idexx Laboratories shares in Q1 2018, an estimated $469K.
Cavalier Investments first reported a position in Idexx Laboratories in Q4 2016 and held it in 5 quarters.
Cavalier Investments's Idexx Laboratories position peaked at $665K in Q2 2017.
646 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2018.

Based on Cavalier Investments's 13F filing for Q1 2018, filed 10 May 2018.